Senti Biosciences, INC 8-K filings

Senti Biosciences reported its second quarter 2024 financial results, highlighted by an $8 million grant from CIRM and the regaining of Nasdaq compliance, while also progressing its clinical trials.

Senti Biosciences has implemented a 1-for-10 reverse stock split of its common stock, effective July 17, 2024, to increase its share price.

Senti Biosciences has amended its agreement with Chardan Capital Markets to update the purchase mechanics of its $50 million equity facility, allowing for intraday VWAP purchases.

Senti Biosciences' stockholders approved an amendment to limit officer liability and authorized a reverse stock split at the company's annual meeting.

Senti Biosciences has appointed Kanya Rajangam as President, while Timothy Lu remains CEO, effective May 14, 2024.

Senti Biosciences announced its first quarter 2024 financial results and provided updates on its clinical programs, including the anticipated start of patient dosing for SENTI-202 and SENTI-301A in Q2 2024.

Senti Biosciences has appointed Yvonne Li as Interim Chief Financial Officer and principal accounting officer, effective after the filing of the Q1 2024 report, while CEO Timothy Lu will serve as interim principal financial officer and principal accounting officer until May 4, 2024.

Senti Biosciences' Chief Financial Officer, Deborah Knobelman, Ph.D., has resigned, effective May 3, 2024, and will transition into a consulting role to assist with the handover.

Senti Biosciences reports its 2023 financial results, highlights the clearance of its IND for SENTI-202, and anticipates first patient dosing in Q2 2024.

Senti Biosciences has received a second extension to meet Nasdaq's minimum bid price requirement, moving to the Nasdaq Capital Market.